Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors

Abstract Inhibitors of epidermal growth factor receptor (EGFR) are commonly used as therapeutic agents in oncology. In contrast to currently used oncological treatments, these inhibitors almost always cause skin- and skin adnex toxicity. About 85% of treated patients develop to a more or lesser exte...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2007-03, Vol.43 (5), p.845-851
Main Authors: Galimont-Collen, A.F.S, Vos, L.E, Lavrijsen, A.P.M, Ouwerkerk, J, Gelderblom, H
Format: Article
Language:English
Subjects:
Acneiform eruption
Acneiform Eruptions - chemically induced
Acneiform Eruptions - therapy
Biological and medical sciences
Classification
Drug Eruptions - classification
Drug Eruptions - therapy
Epidermal growth factor receptor
Hair Diseases - chemically induced
Hair Diseases - therapy
Hair disorders
Hematology, Oncology and Palliative Medicine
Humans
Hyperpigmentation
Inhibitor
Management
Medical sciences
Mucous Membrane - drug effects
Nail Diseases - chemically induced
Nail Diseases - therapy
Neoplasms - drug therapy
Paronychia
Pharmacology. Drug treatments
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Telangiectasias
Tumors
Xerosis cutis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Inhibitors of epidermal growth factor receptor (EGFR) are commonly used as therapeutic agents in oncology. In contrast to currently used oncological treatments, these inhibitors almost always cause skin- and skin adnex toxicity. About 85% of treated patients develop to a more or lesser extent an acneiform eruption. Xerosis cutis and painful nail disorders occur in, respectively, 35% and 10–15% of all treated patients. Also hair and mucosal changes have been reported, although to a lesser extent. These skin- and skin adnex toxicities are reversible after withdrawal of treatment, but are seldom a reason to stop or interrupt therapy. This review outlines the classification, the pathogenesis and therapy of these skin, hair, nail and mucosal changes due to EGFR inhibition. Informing the patient and management of these side-effects is very important to reduce discomfort and as such to increase compliance to therapy.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2006.11.016